Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomised, 30-week Placebo-controlled Phase IV Study to Assess the Efficacy and Safety of Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

NCT07247162 is registered in ClinicalTrials.gov with RECORDATI GROUP as lead sponsor.

NCT NCT07247162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07247162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomised, 30-week Placebo-controlled Phase IV Study to Assess the Efficacy and Safety of Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Lead sponsor
RECORDATI GROUP
Phase
Phase 4
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
July 31, 2028
Enrollment
63 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cushing syndrome, hypercortisolemia, hypertension